Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Melanoma
NCT00002817 · Sidney Kimmel Cancer Center at Thomas Jefferson University, Other · Unknown status
Key facts
| NCT number | NCT00002817 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Melanoma |
| Official title | INTRALESIONAL IMMUNOTHERAPY WITH A VACCINIA/GM-CSF RECOMBINANT VIRUS IN PATIENTS WITH METASTATIC MELANOMA |
| Lead sponsor | Sidney Kimmel Cancer Center at Thomas Jefferson University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | sargramostim, vaccinia-GM-CSF vaccine |
| Enrollment | 30 |
| Start date | Apr 1, 1996 |
| First posted | Jan 22, 2004 |
| Last update posted | Jan 10, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: